Technical Analysis for MGNX - MacroGenics, Inc.

Grade Last Price % Change Price Change
B 15.61 -2.86% -0.46
MGNX closed down 2.86 percent on Friday, April 19, 2024, on 65 percent of normal volume.
Earnings due: May 7
*** please verify all earnings dates ***
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Spinning Top Other 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Fell Below 20 DMA Bearish -2.86%
MACD Bearish Signal Line Cross Bearish -2.86%
NR7 Range Contraction -2.86%
Narrow Range Bar Range Contraction -2.86%

   Recent Intraday Alerts

Alert Time
Down 5% about 20 hours ago
60 Minute Opening Range Breakdown about 22 hours ago
Down 3% about 23 hours ago
20 DMA Resistance about 24 hours ago
Up 1% about 24 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

MacroGenics, Inc. Description

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Immune System Antibodies Autoimmune Disease Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Antibody Novel Cancer

Is MGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.88
52 Week Low 4.29
Average Volume 1,601,673
200-Day Moving Average 9.55
50-Day Moving Average 16.96
20-Day Moving Average 16.10
10-Day Moving Average 17.22
Average True Range 1.17
RSI (14) 44.13
ADX 23.25
+DI 25.16
-DI 26.59
Chandelier Exit (Long, 3 ATRs) 16.02
Chandelier Exit (Short, 3 ATRs) 16.34
Upper Bollinger Bands 19.58
Lower Bollinger Band 12.62
Percent B (%b) 0.43
BandWidth 43.21
MACD Line 0.06
MACD Signal Line 0.15
MACD Histogram -0.0937
Fundamentals Value
Market Cap 968.28 Million
Num Shares 62 Million
EPS 0.81
Price-to-Earnings (P/E) Ratio 19.27
Price-to-Sales 9.37
Price-to-Book 5.54
PEG Ratio 0.01
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.24
Resistance 3 (R3) 17.30 16.82 16.97
Resistance 2 (R2) 16.82 16.40 16.79 16.88
Resistance 1 (R1) 16.21 16.14 15.97 16.15 16.79
Pivot Point 15.73 15.73 15.61 15.70 15.73
Support 1 (S1) 15.12 15.31 14.88 15.07 14.43
Support 2 (S2) 14.64 15.05 14.61 14.34
Support 3 (S3) 14.03 14.64 14.25
Support 4 (S4) 13.98